Dengue Vaccines Market, By End User (Hospitals, Government Institutes, NGOs), and By Region (Latin America, Middle East, Africa, and Rest of World) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Dengue fever is a mosquito-borne viral infection causing a severe flu-like illness. Dengue vaccine is only recommended in those who have previously had dengue fever. It is given as three injections over a year. Dengue is most likely to affect individual's tropical and subtropical countries. Increasing prevalence of dengue is expected to propel growth of the global dengue vaccine market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global Dengue Vaccine and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global Dengue Vaccine based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Sanofi, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, and Merck & Co.
• Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
• The global Dengue Vaccine report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

• Dengue Vaccine Market, By End User:
  • Hospitals
  • Government Institutes
  • NGOs
• Dengue Vaccine Market, By Region:
  • Latin America
    • By End User
    • Hospitals
    • Government Institutes
    • NGOs
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Asia Pacific
    • By End User
    • Hospitals
    • Government Institutes
    • NGOs
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By End User
    • Hospitals
    • Government Institutes
    • NGOs
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By End User
    • Hospitals
    • Government Institutes
    • NGOs
    • By Country:
    • South Africa
    • Central Africa
    • North Africa
  • Rest of World
    • By End User
    • Hospitals
    • Government Institutes
    • NGOs
• Company Profiles
  • Sanofi *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline
  • Merck & Co.

"*" marked represents similar segmentation in other categories in the respective section.